Acute myeloid leukemia (AML) is a malignant disorder of the bone marrow which is
characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells …

ERK1 and ERK2 are related protein-serine/threonine kinases that participate in the Ras-Raf-
MEK-ERK signal transduction cascade. This cascade participates in the regulation of a large …

Gene therapy with LentiGlobin for sickle cell disease (bb1111, lovotibeglogene autotemcel)
consists of autologous transplantation of a patient's hematopoietic stem cells transduced …

T cells expressing anti-CD19 chimeric antigen receptors (CARs) can induce complete
remissions (CRs) of diffuse large B cell lymphoma (DLBCL). The long-term durability of …

Our understanding of the genetics of acute myeloid leukemia (AML) development from
myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation …

Defects in apoptosis underpin both tumorigenesis and drug resistance, and because of
these defects chemotherapy often fails. Understanding the molecular events that contribute …

Key Points Ability to accurately attribute adverse events post–gene therapy is required to
describe the benefit-risk of these novel treatments. A SCD patient developed …

CPX-351 is a liposomal formulation of cytarabine: daunorubicin designed to deliver
synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute …

Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical
trials and thus, population‐based studies are crucial for its accurate characterization. In this …

To study the characteristics and clinical impact of therapy-related acute myeloid leukemia (t-
AML). 200 patients (7.0%) had t-AML and 2653 de novo AML (93%). Patients with t-AML …